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Abstract The ability of the Chagas disease agent Trypanosoma cruzi to resist extended in vivo
exposure to highly effective trypanocidal compounds prompted us to explore the potential for
dormancy and its contribution to failed drug treatments in this infection. We document the
development of non-proliferating intracellular amastigotes in vivo and in vitro in the absence of
drug treatment. Non-proliferative amastigotes ultimately converted to trypomastigotes and
established infections in new host cells. Most significantly, dormant amastigotes were uniquely
resistant to extended drug treatment in vivo and in vitro and could re-establish a flourishing
infection after as many as 30 days of drug exposure. These results demonstrate a dormancy state
in T. cruzi that accounts for the failure of highly cytotoxic compounds to completely resolve the
infection. The ability of T. cruzi to establish dormancy throws into question current methods for
identifying curative drugs but also suggests alternative therapeutic approaches.
DOI: https://doi.org/10.7554/eLife.34039.001
Introduction
Parasitic diseases have been particularly resistant to the development of effective vaccines and safe
and curative therapeutic drugs. The drugs that have been put into use often suffer from one or more
of the problems of inefficiency, high toxicity and/or selection of drug resistant mutants.
Despite being one of the highest impact infectious diseases in the Americas, T. cruzi infection in
humans is relatively rarely treated. Initially this was because of the misconception that Chagas dis-
ease had an autoimmune, rather than pathogen persistence etiology (Tarleton, 2003) but more
recently the substantial toxic side effects and the limited supply of benznidazole (BZN) and nifurti-
mox (NFX), drugs that have been in use for decades, has also contributed significantly to their low
rate of utilization. However, the highly variable outcome of treatment regimens employing these
compounds – ranging from 0% to 100% depending on the study - and the difficulty of accurately
assessing these outcomes, also keep utilization as low as 1% of those infected (de Castro et al.,
2006; Guedes et al., 2011; Jackson et al., 2010; Navarro et al., 2012; Yun et al., 2009).
The reason for the high variability in the efficacy of BZN and NFX is not known but has been pri-
marily attributed to the broad genetic diversity of T. cruzi isolates. Importantly, the lack of drug effi-
cacy is almost certainly not a result of selection of genetic resistance by drug use or misuse, as
neither BZN nor NFX have been widely or indiscriminately used and the induction of stable resis-
tance to these drugs is difficult to produce in vitro or in vivo. Further, the variable and often low con-
tribution of humans to infection of insect vectors (many infections in insects originate from feeding
on non-human mammals, within which T. cruzi circulates widely and at high levels [Cohen and Gu¨r-
tler, 2001]), offers very few opportunities to drive and spread resistance even if it were to develop.
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In addition to classical genetic-based drug resistance, it has become increasingly appreciated
that in bacterial infections, ‘persister’ cells develop that are transiently unaffected by chemotherapy,
due in most cases to metabolic dormancy (reviewed in [Harms et al., 2016]). Such persisters can
arise spontaneously in the presence or absence of stress signals and can reemerge after the termina-
tion of environmental challenges – such as antibiotic treatment.
In this study, we document the occurrence of dormancy in the protozoan T. cruzi and link this
phenomenon to the resistance of this parasite to otherwise highly effective and cytotoxic drugs. We
show that both in vitro and in vivo, T. cruzi exhibits a biphasic kill curve, with the rapid death of most
parasites but the persistence of transiently non-replicating intracellular parasites that are resistant to
high level and prolonged drug exposure.
Results
The anti-T. cruzi drugs BZN and NFX are normally dosed in animals (including humans) for 30–60
days, although shorter treatment times can occasionally be curative (Bustamante et al., 2014;
Viotti et al., 2011). This general requirement for a long treatment course and the variability in out-
come is inconsistent with the documented rapid trypanocidal activity of BNZ for T. cruzi in vitro
(Moraes et al., 2014), although to our knowledge, kill rates had not previously been determined in
vivo. To directly assess the activity of BNZ in vivo, we first established a localized infection of T. cruzi
in the footpads of mice and then used a transgenic luciferase reporter to monitor the loss of para-
sites subsequent to a single oral dose of BNZ. We first determined that T. cruzi trypomastigotes
delivered in the footpad or skin, primarily infect host cells at the infection site (rather than distribut-
ing systemically) and expand as amastigotes within these host cells during the subsequent ~96 hr
(Padilla, et al., in preparation). Administration of a single oral dose of BZN reduced intracellular
amastigotes at the initial infection site by ~90% within 48 hr (Figure 1A–C). A similarly rapid reduc-
tion in parasite load occurs in mice with established systemic infections within a few days after the
initiation of oral BZN treatment (Figure 1D–F). In this later experiment we used multiple T. cruzi iso-
lates, including two (colombiana and ARC-0704) previously determined to be relatively more
eLife digest Chagas disease is one of the most harmful tropical diseases in the Americas. It
affects millions of people, predominantly in Latin America. It is usually spread by kissing bugs
infected with Trypanosoma cruzi parasites. It is considered a neglected tropical disease because few
effective treatments and preventive methods are routinely used.
Several drugs can kill T. cruzi parasites, but they often fail to cure the infection. Many people with
Chagas disease go on to have life-long infections and eventually develop heart failure. The reason
for the high rate of treatment failure is not known. It does not appear to be the result of the
parasites developing resistance to the drugs. One possibility is that the parasites can hide in a
dormant state in the body, dodging the toxic drugs and living to reproduce another day.
Now, Sa´nchez-Valde´z et al. identify a dormant form of the T. cruzi parasite that allows the
infection to persist after treatment. In the experiments, a non-reproducing form of the so-called
amastigote stage of the T. cruzi parasite inside the host cells was observed in infected mice and
human cells. While some of the amastigote parasites continue multiplying, a few stop even without
drug treatment – but can resume multiplication at a later time. They may also be able to change into
the trypomastigote form of the parasite, which can infect new cells. These non-multiplying
amastigotes can survive drug treatment for as long as 30 days, whereas the multiplying amastigotes
are killed by such drugs. However, the surviving amastigotes then reestablish active infections after
treatment has stopped.
The experiments explain why treatment so often fails to cure Chagas disease. This suggests new
treatment strategies are needed, including using existing drugs for a longer time perhaps with less
frequent doses. New therapies that kill the dormant amastigotes may also help. Treatments that
overcome the parasite’s ability to hide, could stop the progression of the disease and prevent heart-
related deaths in those with persistent T. cruzi infections.
DOI: https://doi.org/10.7554/eLife.34039.002
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resistant to BZN in vivo (Bustamante et al., 2014). The rate of parasite clearance, approaching the
limit of detection by imaging, was similar for all three strains and in the case of the colombiana infec-
tion, the 5 days of treatment resulted in a > 3 log10 reduction in systemic parasite load. Thus, consis-
tent with previous in vitro assessments, BZN rapidly and highly effectively kills both ‘resistant’ and
‘susceptible’ T. cruzi strains in vivo.
While these experiments demonstrate that BZN treatment rapidly reduces T. cruzi numbers by
10- to 1000-fold over just a few days, we know from previous studies that such short-term treat-
ments, and indeed treatments as long as 60 days, often fail to completely clear T. cruzi infection
(Bustamante et al., 2014). This disconnect implicates a mechanism by which T. cruzi can resist highly
effective trypanocidal drugs for an extended period of time. To investigate whether dormant/non-
Figure 1. Rapid decrease of parasite load following short-term BZN treatment. (A) Schematic experimental protocol. C57BL/6 mice were infected in the
hind footpads with 2  105 luciferase-expressing T. cruzi trypomastigotes of the CL-3 strain. A single oral dose of BZN (100 mg/kg) was administered 2
days post-infection. Cohorts of mice were maintained as untreated controls. Parasite bioluminescence following D-luciferin injection was measured at 6,
12, 18, 24 and 48 hr after BZN dosing. (B) Representative images showing footpad bioluminescent signal 2 days post-infection and at 6, 12 and 48 hr
post-treatment. The heat map is on a log10 scale and indicates the intensity of bioluminescence from low (blue) to high (red). (C) Quantification of
footpad signal. Each data point represents the mean of 12 footpads bioluminescence from six mice expressed on a logarithmic scale. After subtraction
of the background signal, total flux measurements of photons per second (p/s) were quantified. A statistically significant difference (p=0.004) was found
between treated (blue) and untreated (red) groups. (D) Protocol to measure systemic parasite load by bioluminescence before and during daily dosing
with BZN. Cohorts of six SKH-1/B6 (hairless C57BL/6) mice were infected i.p. with 5  105 colombiana, ARC-0704 or CL-3 luciferase-expressing T. cruzi
isolates. Oral BZN-treatment (100 mg/kg/day) was initiated on day 12 and continued until day 17 post-infection. (E) Dorsal (D) and ventral (V) images of
individual representative infected mice. (F) Quantification of whole animal ventral bioluminescence. Dashed line indicates detection threshold
determined as the mean plus two standard deviation of background bioluminescence of uninfected mice. Untreated control animals infected with all
the strains showed similar high parasite levels, representative images (E) and data (F) for the group infected with colombiana strain are shown. No
statistical differences were observed in the rate of parasite decrease between strains (p=0.29). Results are representative of three independent
experiments with six infected animals per parasite strain group.
DOI: https://doi.org/10.7554/eLife.34039.003
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Figure 2. Rare amastigotes fail to incorporate EdU in chronically infected mice. (A) Experimental protocol for assessing proliferation of amastigotes in
established in vivo infections. C57BL/6 mice were infected with 2.5  105 trypomastigotes of colombiana T. cruzi strain co-expressing fluorescent
(Tdtomato) and luminescent (luciferase) reporter proteins. Sixty days post-infection, mice were injected i.p. with EdU and sacrificed 24, 48 or 72 hr after
injection. Mice were perfused with PBS and luciferin and ex vivo bioluminescence imaging of selected tissues were performed to identify parasite foci.
Figure 2 continued on next page
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replicating forms of T. cruzi might be present in infected hosts and possibly contributing to this
requirement for long treatment regimens, we used in situ labeling with nucleotide analog 5-ethynyl-
2’-deoxyuridine (EdU) to determine the replication status of parasites within tissues of infected mice.
We first established the in vivo EdU labeling protocol in acutely infected mice with high tissue para-
site load, finding that the vast majority of amastigotes incorporated EdU during a 24 hr period after
EdU injection (Figure 2—figure supplement 1). We then applied this protocol to mice with estab-
lished chronic T. cruzi infections and again found that most intracellular amastigotes incorporated
EdU over the 24–72 hr of exposure. However a small fraction of intracellular amastigotes failed to
show evidence of replication over the 72 hr after EdU injection (Figure 2—figure supplement 2).
Interestingly, these apparently non-replicating amastigotes were within host cells in which the other
amastigotes were clearly replicating, suggesting that there is a heterogeneity of amastigotes in
infected cells. Since the low parasite load in chronically infected mice makes it highly unlikely that a
single host cell is infected by more than one trypomastigote, this heterogeneity in replication
appears to establish within host cells from a single infecting parasite Figure 2.
To examine in greater detail the replication pattern of T. cruzi in host cells, we moved to in vitro
systems wherein large numbers of infected cells can be readily monitored longitudinally during infec-
tion and the continuous exposure to EdU can be assured. As in the in vivo infection, a small fraction
of amastigotes in host cells in vitro consistently failed to take up EdU, even when exposed for up to
72 hr of the ~96 hr intracellular replication phase (Figure 3). One possible reason for the failure to
replicate is that some amastigotes might die within host cells (perhaps as a result of lethal damage
to DNA, defective cytokinesis, or unequal dispersal of chromosomes/organelles during prior replica-
tion, among other possible reasons). However monitoring for apoptosis of amastigotes in host cells
revealed this process to be extremely rare (Figure 3—figure supplement 1).
Incorporation of EdU into DNA can impact DNA replication and thus cell division (Zhao et al.,
2013). To rule out a role for EdU itself in inhibition of parasite replication, we used the cell division
tracker dyes carboxyfluorescein succinimidyl ester (CFSE) and CellTrace Violet as a second method
to monitor parasite replication in host cells. Both dyes couple to cellular components and are equally
distributed to daughter cells during cytokinesis and with vigorous replication, the dyes are eventually
diluted beyond the point of detection. T. cruzi trypomastigotes uniformly stain with either dye and
upon infection of host cells, replicating amastigotes dilute the dye, while a fraction of amastigotes
remain dye positive, indicating again the limited replication of a subset of amastigotes (Figure 4A
and B). Amastigotes remaining dye positive after 72–96 hr were also EdU-negative (Figure 4C).
By continuing to monitor infected host cells over time, we observed that amastigotes that had
failed to incorporate EdU during the final ~72 hr in host cells were fully competent to convert to try-
pomastigotes and to exit host cells, along with the previously replicating (EdU+) trypomastigotes
(Figure 4D,E). The use of the CellTrace Violet to mark parasites that had undergone a limited num-
ber or no divisions during the infection cycle in host cells allowed us to further characterize and ulti-
mately isolate this minority population of trypomastigotes from infected cell cultures (Figure 4F and
G), and to assess their ability to establish a second round of infection/replication in new host cells.
Not only could trypomastigotes from minimally replicating amastigotes infect new host cells, re-con-
vert to amastigotes (Figure 5A), and begin a new round of replication, but progeny of this replica-
tion can also stop dividing soon after invasion and retain dye for >6 days while other progeny of this
dormant amastigote divided extensively (Figure 5B). Thus, a small proportion of T. cruzi amastigotes
Figure 2 continued
Luciferase-positive thick tissue sections were clarified and Tdtomato + parasites and EdU incorporation was detected by confocal microscopy.
Colocalization of Tdtomato (red) and EdU (green) positive signals identifies proliferating amastigotes (yellow nuclei) from (B) skeletal and (C) adipose
tissue. Arrows indicate rare red only (non-proliferating) amastigotes. Scale bars, 5 mm. HCN = EdU positive host cell nuclei. Results are representative of
three independent experiments using groups of 2–3 mice.
DOI: https://doi.org/10.7554/eLife.34039.004
The following figure supplements are available for figure 2:
Figure supplement 1. Detection of proliferating amastigotes in acutely infected mice.
DOI: https://doi.org/10.7554/eLife.34039.005
Figure supplement 2. Detection of non-proliferating amastigotes in established infections.
DOI: https://doi.org/10.7554/eLife.34039.006
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Figure 3. Non-replicating amastigotes are also evident in vitro. Nearly confluent monolayers of Vero cells were infected with trypomastigotes of
colombiana, CL, Brazil or ARC-0704 T. cruzi strain. Twelve hours after infection, cultures were washed and incubated with EdU (100 mM) diluted in fresh
RPMI medium. EdU was detected after an additional 24, 48 or 72 hr culture period. DAPI staining (blue) allows the identification of EdU-negative
amastigotes (arrows) from the EdU-positive (green). HCN, host cell nuclei. Scale bars, 5 mm. Results are representative of three independent
experiments.
DOI: https://doi.org/10.7554/eLife.34039.007
The following figure supplement is available for figure 3:
Figure supplement 1. Rare apoptosis of amastigotes in host cells.
DOI: https://doi.org/10.7554/eLife.34039.008
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halt replication within 24 hr after host cell entry but can convert to trypomastigotes that are infec-
tion-competent and able to repeat the processes of replication and arrested replication in new host
cells (Figure 5C).
The detection of a small subpopulation of T. cruzi amastigotes undergoing minimal replication
through 2 rounds of host cell invasion suggests that the cessation of replication can at a minimum
happen early after host cell invasion, but did not preclude a more dynamic pattern of transitioning
between replication and dormancy during the infection cycle in host cells. In order to better under-
stand the flexibility and heterogeneity of replication within host cells, we monitored the early replica-
tion of T. cruzi in host cells by time-lapse video, using violet dye dilution to help mark those
parasites undergoing minimal cell division within the same cell where other parasites are actively
dividing (Sup Videos 1 and 2).These videos also indicate other characteristics of non-dividing amas-
tigotes that were apparent in other still images, for example that non-dividing amastigotes are
Figure 4. Non-proliferating amastigotes can transition to trypomastigotes. (A, B) Td-tomato expressing T. cruzi trypomastigotes were labeled with
CellTrace Violet and used to infect Vero cells. Amastigote replication was monitored for 72–96 hr post-infection by live imaging (A) and confocal
microscopy (B). Note the violet signal dilution in proliferating amastigotes and the retention of the dye in the non-replicating amastigote (arrows). (C)
Vero cell cultures infected with CellTrace Violet-labeled T. cruzi trypomastigotes were incubated with EdU (100 mM) for 72 hr before fixation and
detection of EdU incorporation. CellTrace Violet-positive amastigotes were also EdU-negative (arrow). Experiment was performed three times. (D)
Schematic of the experimental protocol. T. cruzi colombiana strain trypomastigotes expressing Tdtomato were used to infect nearly confluent
monolayers of Vero cells. Twelve hours after infection, the dishes were washed and incubated with EdU (100 mM) for 72 hr. Cultures were fixed,
permeabilized and EdU (green) detection was performed just prior to trypomastigote release from host cells (~96 hr post-infection). (E) Arrowheads
indicate EdU-negative trypomastigotes (red only) within host cells filled with EdU-positive trypomastigotes (green). (F, G) Violet-labeled Td-tomato-
expressing trypomastigotes (colombiana or CL strains) were used to infect Vero cell cultures. Trypomastigotes released 92 hr post-infection were
harvested by centrifugation and flow-imaged by ImageStream and sorted via fluorescence-activated flow sorting. Only a small subpopulation of
trypomastigotes retained substantial CellTrace Violet after a single round of host cell infection. Similar results were obtained with CFSE staining of
trypomastigotes (not shown). Scale bars, 5 mm. Experiment was performed a minimum of three times.
DOI: https://doi.org/10.7554/eLife.34039.009
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similar in size to recently divided amastigotes and are generally Tdtomato-dim, expressing low levels
of the Tdtomato fluorescent protein relative to rapidly dividing amastigotes.
These results show conclusively that within host cells infected with T. cruzi, a subset of amasti-
gotes cease replication while others continue rapid division, eventually filling the host cell with amas-
tigotes. The obvious question remaining is ‘Does this cessation of replication play a critical role in
the failure of drugs to effectively clear T. cruzi infection?’ More specifically, are these replication-
arrested parasites resistant to drug treatment? To directly address these questions, we infected
mice with Tdtomato-expressing and CellTrace Violet-stained trypomastigotes and confirmed 2 days
post-infection the presence in adipose tissue of parasites displaying both of these markers
(Figure 6A and B). As expected based on previous experiments, over the span of the 2 day
Figure 5. Trypomastigotes originating from non-replicative amastigotes are able to infect host cells and produce both replicating and dormant
progeny. (A) Violet-positive trypomastigotes obtained as shown in Figure 4G were used to infect a fresh culture of Vero cells. Infected cells with
CellTrace Violet-positive amastigotes were observed 24 hr post-infection (arrow). (B) Six days post-infection, a non-dividing CellTrace Violet-positive
progeny was identified (arrow) in cells filled with dye-negative trypomastigotes. (C) Experiment summary: CellTrace Violet-positive trypomastigotes can
produce both dormant (violet+) and actively replicating (violet-) progeny, both of which can convert to trypomastigotes. The trypomastigotes from
previously dormant amastigotes can infect new host cells and repeat the process of generating both dormant and actively replicating progeny. Scale
bars, 5 um. Experiments repeated twice.
DOI: https://doi.org/10.7554/eLife.34039.010
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infection, several strongly violet-positive parasites
are obvious in cells along with a larger number of
parasites in which the violet dye was faint or not detectable, indicating both slow or non-replicating
and actively replicating progeny of the infecting trypomastigotes. On days 2 and 3, similarly infected
mice were treated with BZN or left untreated and on day 4, examined for the presence of parasites.
Remarkably, in the BZN-treated mice, the only parasites detected were brightly violet and present
at 1 and occasionally two per infected cell (Figure 6B and Figure 6—figure supplement 1). Actively
replicating parasites (violet-negative) were not detected in the BZN-treated mice while a much larger
number of violet-negative and less abundant violet-positive parasites were observed in the non-
treated mice. A resumption of parasite replication was evident in treated mice 9 days after the last
of the 2 BNZ treatment doses, demonstrating that dormant, and therefore drug resistant amasti-
gotes, could also resume division in vivo. To further address the drug resistance and recovery poten-
tial of dormant amastigotes in vivo, we repeated these experiments in interferon-gamma deficient
mice, which lack the ability to develop immune control of T. cruzi infection. Non-replicating amasti-
gotes developing in these mice survive a minimum of 20 days of BZN treatment (Figure 6—figure
supplement 2A) and again resume replication upon cessation of BZN treatment (Figure 6C) and
eventually spread extensively in these animals (Figure 6—figure supplement 2B,C).
Tracking very low numbers of persisting parasites in vivo in drug-treated, infected animals is quite
difficult, so we returned to in vitro systems to examine the resistance of T. cruzi to drug treatment
over longer time periods and the association between drug resistance and dormancy. Here we
infected host cells 24 hr previously with Tdtomato-expressing and CellTrace Violet-labeled parasites
and then added BZN at 10X the IC50 for up to 30 days of culture before washing out the drug. Para-
site recovery following drug treatment/washout was monitored globally by whole-well fluorescence
detection of the Tdtomato reporter, and at the individual cell level by microscopy (Figure 7). In the
absence of treatment, parasite numbers peak near the time of the completion of the first round of
intracellular replication (~day four after infection). In all cases, even following 30 days of high dose
BZN treatment, parasites can rebound and begin replication after BZN is removed. This rebound
can often be observed in the whole well Tdtomato fluorescence readings (Figure 7A), and in all
Video 1. Time lapse video of early stage intracellular
replication of T. cruzi amastigotes. Cultures of HFF cells
in 96 well glass bottom plates were infected with
Tdtomato-expressing Cell Trace Violet labeled
trypomastigotes in a ratio of 10:1 (parasites: host cells).
After a5hrincubation, cultures were washed to remove
extracellular parasites and imaged every 15 min for
48hr. Time lapse videos were generated spanning from
15:45 to 31:30hr. Note the dye-retaining amastigote
(blue) remaining undivided while other amastigotes in
the same cells (bright orange amastigotes) actively
proliferate.
DOI: https://doi.org/10.7554/eLife.34039.011
Video 2. Time lapse video of early stage intracellular
replication of T. cruziamastigotes. Cultures of Vero cells
in 96 well glass bottom plates were infected with
Tdtomato-expressing CellTrace Violet labeled
trypomastigotes in a ratio of 5:1 (parasites: host cells).
After a5hrincubation, cultures were washed to remove
extracellular parasites and imaged every 15 min for
48hr. Time lapse videos were generated spanning from
9:30 to 47:15hr. Note the dye-retaining amastigote
(blue amastigote denoted by white asterisk at the
beginning of Video 1) remaining undivided while other
amastigotes in the same cell (bright orange
amastigotes) actively proliferate.
DOI: https://doi.org/10.7554/eLife.34039.012
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cases, low numbers of parasites with a range of violet dye retention are evident in cultures during
drug treatment (Figure 7B), as well as resumption of low level to vigorous replication after drug
washout (Figure 7C). The resistance of T. cruzi to drug treatment due to amastigote dormancy was
not restricted only to BNZ, as members of a class of newly developed oxaborale compounds cur-
rently under preclinical development also failed to overcome dormancy-dependent resistance in
vitro (Figure 7—figure supplement 1). Further, T. cruzi lines rebounding after 30 days of in vitro
exposure to BZN had not developed stable resistance to the compound as the IC50 of BZN on this
population remained unchanged from that of the pre-exposed population (Figure 7—figure supple-
ment 2).
Thus, T. cruzi amastigotes regularly and spontaneously cease replication and in that dormant
state are resistant to otherwise highly effective trypanocidal drugs for extended periods of time.
Figure 6. Only dormant amastigotes are resistant to short-term in vivo BZN treatment. (A) Schematic of experimental protocol. (B) C57BL/6 mice were
infected i.p. with 5  106 Td-Tomato-expressing and CellTrace Violet-labeled trypomastigotes and orally treated with BZN (100 mg/kg/day) on day 2
and 3 post-infection or left untreated. At the indicated time points, mice were euthanized and adipose tissue was excised, fixed and processed for
confocal imaging. Images are representative of three independent experiments with 3–4 animals per group. (C) Infection with 1.5  107 Td-Tomato-
expressing and CellTrace Violet-labeled trypomastigotes was established for 6 days in IFN-g deficient mice before initiation of daily treatment with BZN
(100 mg/kg) for 12 days. Peritoneal adipose tissue was harvested from mice on day 6 (prior to treatment), at the end of the 12 day treatment period on
day 18 post-infection, or 14 days after the end of treatment (32 dpi). The peritoneal adipose tissue sample from each mouse is ~0.3 g of tissue spread
over a surface of ~1.6 cm2 when mounted for microscopic analysis. In tissue harvested on day 6 of infection (prior to treatment), infected cells can be
observed within 15 min of scanning. Following 12 days of treatment this same amount of tissue must be exhaustively scanned for up to 3 hr per sample
to detect between 4 and 5 infected cells per sample. Images are representative of two independent experiments with four animals each.
DOI: https://doi.org/10.7554/eLife.34039.013
The following figure supplements are available for figure 6:
Figure supplement 1. Residual CellTrace Violet-labeled amastigotes after BZN treatment.
DOI: https://doi.org/10.7554/eLife.34039.014
Figure supplement 2. Dormant amastigotes resist up to 20 days of BNZ treatment in vivo and are able to rebound after treatment cessation.
DOI: https://doi.org/10.7554/eLife.34039.015
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Figure 7. Dormant amastigotes are resistant to extended BNZ treatment in vitro. Vero cell cultures were infected with Tdtomato-expressing
trypomastigotes of colombiana or CL strains (5:1 ratio parasites:cells) 24 hr prior to addition of BNZ (10 uM). At various times post-treatment, BNZ was
removed from the cultures and the subsequent rebound of parasites surviving the drug treatment was determined by whole well fluorescence intensity
reading (A) and in vitro live imaging (B, C). The retention of the CellTrace Violet label during the course of BNZ treatment indicates that the BNZ-
resistant parasites are dormant (B) and capable of replication after drug washout (C). Results are representative of three independent experiments with
six replicates per condition. Arrow to inset in (A) shows reading of individual replicate wells.
DOI: https://doi.org/10.7554/eLife.34039.016
Figure 7 continued on next page
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These dormant parasites are capable of re-initiating replication after >30 days of drug exposure and
perhaps much longer after the initiation of dormancy.
Discussion
Although T. cruzi infection is one of the highest impact infectious disease in the Americas, including
in the United States, effective prevention, control and treatment methods are virtually non-existent.
A rare bright spot in potential interventions for Chagas disease is the increased availability of drugs
such as BZN, which have substantial curative efficacy. However, although BZN and NFX have been in
use for decades, have relatively clear mechanisms of action and do not appear to readily encourage
development of genetic-based drug resistance, their unpredictable treatment outcome coupled with
their modest to severe side effects has limited their use primarily to acute, childhood, or immuno-
suppression-exacerbated infections. This situation leaves largely untreated the millions of individuals
with chronic T. cruzi infection, many of whom will eventually develop chagasic cardiomyopathies.
Furthermore, human clinical trials of new therapies judged to be promising based upon limited stud-
ies in experimental models have been colossal failures (Molina et al., 2014; STOP-
CHAGAS Investigators et al., 2017) and ClinicalTrials.gov identifiers NCT01489228, NCT02498782,
and NCT01162967), demonstrating these compounds to be clearly inferior to BNZ and NFX.
This study initially sought to determine why compounds like BZN that can, and often do, provide
sterile cure in T. cruzi infection, also frequently fail. This and previous studies have largely ruled out
several mechanisms as primary reasons for the variable efficacy of BZN. Although there is parasite
strain variation with respect to BZN susceptibility in vivo, this variation does not appear to be due to
direct resistance to the trypanocidal activity of BZN (Figure 1). Parasite lines obtained from failed
drug treatments are no more resistant to BZN than the pre-treatment parasites (Sup Figure 7), and
although BZN resistance can be induced by drug selection in vitro, such partially resistant lines are
crippled with respect to initiating and maintaining an infection (Mejia et al., 2012). Thus resistance
to BZN treatment is relative, not complete, is not easily selectable, and is not associated with any
specific genetic lineage of T. cruzi nor with host genetics.
The results of the current study firmly connect drug treatment failure in T. cruzi infection to the
presence of a previously unrecognized player in this parasite’s life cycle, the transiently dormant
amastigote. We denote these stages as dormant based primarily on their failure to replicate over an
extended period of time and their resistance to trypanocidal compounds over >30 days of exposure.
These dormant amastigotes appear at a consistently detectable frequency and are present in many
infected host cells in vitro and in vivo. Dormancy occurs spontaneously and is often observed soon
after host cell infection – as shown by the ability of parasites to retain cell division monitoring dyes
through several rounds of host cell invasion and expansion. However dormancy may also occur at
other points throughout the 4–5 day replication cycle within host cells, as suggested by the presence
of multiple EdU-negative amastigotes in heavily infected cells and supported by time lapse imaging
of infected cells. Importantly, these dormant parasites are not permanently arrested, as they resume
replication days to weeks after entering dormancy (Figure 7). These dormant amastigotes also read-
ily respond to the cues that drive conversion to trypomastigote forms within host cells, a process
that appears to occur only when the host cell is nearly bursting with amastigotes. Candidates for the
inducer of stage conversion would include depleted host cytoplasmic components or byproducts of
parasite metabolism that could accumulate inside the host cell. Thus the dormant amastigotes have
two potential fates besides continued dormancy: to re-initiate replication like conventional amasti-
gotes – likely to occur when there are none or a limited number of other amastigotes in the cell - or
to convert to trypomastigotes in concert with the actively replicating amastigotes undergoing that
Figure 7 continued
The following figure supplements are available for figure 7:
Figure supplement 1. Dormant amastigotes are resistant to extended oxaborale treatment in vitro.
DOI: https://doi.org/10.7554/eLife.34039.017
Figure supplement 2. Amastigotes surviving 30 days in vitro BZN treatment have unaltered susceptibility to BZN.
DOI: https://doi.org/10.7554/eLife.34039.018
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process within the same cells. An extremely rare outcome for amastigotes in host cells is death, as
determined by the paucity of degrading amastigotes detected in host cells (Sup Figure 3).
Dormancy is well-studied in bacteria and plays a critical role in their adaptation to changing envi-
ronments. This phenomenon had been missed by previous investigations in T. cruzi likely because
extended dormancy (which would be required to survive during weeks of drug treatment) is rela-
tively rare. In vitro studies often report very high efficiency of drugs such as BZN to kill >99% of T.
cruzi amastigotes – and the assumption has been that this was in fact 100% killing (Moraes et al.,
2014), but this is clearly not the case. To our knowledge, this is the first report of extended dor-
mancy in an otherwise replicating stage of any trypanosomatid. In the related protozoan Leishmania
sp, intracellular amastigotes exhibit greatly reduced proliferation and metabolism relative to the
extracellular promastigote forms (Jara et al., 2017) and have been described as ‘semi-quiescent’
but steadily replicating in vivo with a doubling time of 12 days for L. mexicana (Kloehn et al., 2015).
Studies in L. major by Mandell and Beverley documented slow growing (~60 hr doubling time) and
even slower dividing, BrdU-non-incorporating intracellular amastigotes in mouse infections but the
technical limitations of the labeling procedure prevented a definitive conclusion of dormancy
(Mandell and Beverley, 2017). The dormancy we describe here for T. cruzi is clearly very distinct
from but perhaps most similar to the scantly studied arrested hypnozoite liver stages of Plasmodium
vivax. Hypnozoites appear responsible for relapse of vivax malaria even years after the initial infec-
tion (Markus, 2012), although studies in human liver chimeric mice suggest that hypnozoites may
actually not be fully metabolically inactive (Mikolajczak et al., 2015).
Cyst stages of apicomplexans such as Toxoplasma gondii and Cryptosporidium sp exhibit greatly
reduced if not fully quiescent metabolism, consistent with a life cycle stage that is resistant to poten-
tially harsh environmental conditions associated with transmission to a new host. For T. cruzi it is
much less clear what the evolutionary advantage of dormancy is since transmission depends on put-
ting extracellular parasites into the mammalian host bloodstream for ingestion by its blood feeding
reduviid vector. Although we show that dormancy provides a degree of protection from drug-medi-
ated clearance, drug resistance itself cannot be the selective force for this developmental pathway
as all the T. cruzi lines we have examined, including ones that had not been previously exposed to
these or other drugs, generate dormant amastigotes.
If dormancy is programmed and essential for T. cruzi survival, then the property would seem
most likely associated with evasion of host immune responses, the major stressor with which T. cruzi
amastigotes have to contend. T. cruzi induces a robust and highly effective immune response that
greatly reduces parasite transmission to insect vectors. Although it is relatively rare, this immune
response can lead to complete resolution of the infection (Dias et al., 2008; Tarleton, 2013;
Viotti et al., 2006). Dormancy could facilitate parasite persistence if some trypomastigotes entering
host cells immediately went quiescent and as a result were not detected by the immune system.
Such persisters could then ‘wake-up’ and begin replication weeks or months later. But those reawak-
ened parasites would likely remain low in numbers as they would have to contend with the now
established anti-T. cruzi immune response in order to expand and have an increased chance of being
transmitted. Thus the selective pressure for development or retention of a dormancy pathway for
this purpose alone seems very low.
Alternatively, dormancy might be a consequence of the biology of T. cruzi, rather than an evolu-
tionarily selected process for low-level persistence. T. cruzi very rarely undergoes sexual recombina-
tion but instead depends heavily on gene amplification and recombination, as well as horizontal
gene transfer, for generating genetic diversity. The resorting of genetic material likely takes place in
amastigotes, one of the two replicating stages in the T. cruzi life cycle. Parasites that enter dormancy
soon after host cell invasion could be pre-recombination, ‘stem-like’ cells that would be useful
should the genetic recombination events in the replicating parasites go awry. Alternatively, parasites
might enter dormancy in order to sort out the result of recombination events before proceeding
with additional rounds of replication.
Whether stochastic or programmed, the mechanisms for entering and exiting the dormant state
by T. cruzi is a complete black box. Hints about the process may come from understanding the
events involved in transitioning from replicating stages to non-replicating stages in T. cruzi (e.g. epi-
mastigotes to infective metacyclic trypomastigote and amastigote to blood stage trypomastigote)
or in the related African trypanosome Trypanosoma brucei, which although lacking an intracellular
stage, makes several well-characterized transitions from replicating to non-replicating forms.
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The biggest practical message from the current study is that dormancy in the mammalian infec-
tion cycle of T. cruzi is key to the failure of current drug treatments for T. cruzi infection. While other
factors, including the differential tissue tropism of parasite strains and tissue distribution of potential
drugs, certainly also impact treatment outcomes, only dormancy has been definitively linked. Given
this new understanding of dormancy and its impact on drug treatment, simply identifying more com-
pounds that effectively kill metabolically active parasites is not likely on its own to be the solution to
achieving more dependable cure in T. cruzi infection. The development of new assays that can
screen for compounds capable of overcoming dormancy should also be part of the paradigm for
identifying new, more effective compounds. The use of current drugs in extended, less intensive
dosing routines (A´lvarez et al., 2016; Bustamante et al., 2014) that extend beyond the dormancy
potential of T. cruzi, in place of the current highly intensive regimens, should also be further
explored.
Materials and methods
Key resources table
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
Strain, strain background Trypanosoma cruzi RRID:NCBITaxon:5693
Strain, strain background
(Trypanosma cruzi,
colombiana)
TdTomato and luciferase
coexpresors; Luciferase- and
Tdtomato-expressing parasites.
this paper NA Cotransfected with pTREX-Luciferase
and pTREX-Td-tomato plasmids.
Strain, strain
background
(T. cruzi, colombiana)
Colombiana strains
expresing luciferase
this paper NA Transfected with the pTREX-
Luciferase plasmid.
Strain, strain
background (T. cruzi, CL3)
CL-3 strain expresing
luciferase
this paper NA Transfected with the pTREX-
Luciferase plasmid.
Strain, strain
background
(T. cruzi, ARC0704)
ARC-0704 strain expresing
luciferase.
this paper NA Transfected with the pTREX-
Luciferase plasmid.
Strain, strain
background
(T. cruzi, colombiana)
TdTomato expresing
parasites.
this paper NA Transfected with pTREX-
Tdtomato plasmid.
Cell line VERO 76 American Type Culture
Collection (ATCC)
CRL 1587;
RRID:CVCL_0603
Cell line Human Foreskin
Fibroblasts (HFF)
other N/A HFF cells were a gift from
Dr. D. Etheridge
(University of Georgia)
Recombinant DNA reagent pTREX-Luciferase (plasmid) Canavaci et al., 2010.
PMID: 20644616
NA Addgene 48337
Recombinant DNA reagent pTREX-Tdtomato (plasmid) Canavaci et al., 2010.
PMID: 20644616
NA Addgene 47975
Commercial assay or kit Click-iT EdU Imaging Kit ThermoFisher Scientific,
Waltham, MA
C10337 Cell proliferation detection kit
Commercial assay or kit Click-iT TUNEL Alexa
Fluor 647 imaging assay
ThermoFisher Scientific,
Waltham, MA
C10247 Cell apoptosis detection kit
Commercial assay or kit CellTrace Violet fluorescent dye ThermoFisher Scientific,
Waltham, MA
C34557 Cell proliferation detection kit
Commercial assay or kit CFSE fluorescent dye ThermoFisher Scientific,
Waltham, MA
C34554 Cell proliferation detection kit
Chemical compound, drug D-luciferin PerkinElmer, Waltham,
MA
122799 luciferase substract reagent
Chemical compound, drug CUBIC clarifying solution other NA 25 % N,N,N0,N0-Tetrakis
(2-hydroxypropyl)ethylenediamine;
25% urea; 15% Triton X-100
and distilled water (Susaki et al., 2015)
Continued on next page
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Continued
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
Chemical compound, drug Benznidazole (N-benzyl-2
-nitro-1-imidazolacetamida)
LAFEPE medicamentos.
Brazil; Aesica
Pharmaceutical,
United Kingdom
BZN
Chemical compound, drug DAPI stain 4’,6-diamidino-2
-phenylindole dihydrochloride
ThermoFisher Scientific,
Waltham, MA
122799
Software, algorithm Living Image software v4.3 Xenogen, Alameda, CA RRID:SCR_014247
Software, algorithm GraphPad 5.0 Prism v5.0 GraphPad Software, La
Jolla California USA,
RRID:SCR_002798
Other: Mice strains C57BL/6NCr mice Charles River
Laboratories
C57BL/6NCrl - strain
code 027
IFN-g knockout mice The Jackson
Laboratory
B6.129S7-Ifngtm1Ts/J
- stock No 002287
SKH-1 mice other NA The SKH-1 ‘hairless’ mice
backcrossed to C57BL/6 were
a gift from Dr. Lisa DeLouise
(University of Rochester).
Mice
C57BL/6NCr and IFN-g knockout (B6.129S7-Ifngtm1Ts/J) mice were purchased from Charles River
Laboratories and The Jackson Laboratory respectively. The SKH-1 ‘hairless’ mice backcrossed to
C57BL/6 were a gift from Dr. Lisa DeLouise (University of Rochester). All mice were maintained in
the University of Georgia Animal Facility under specific pathogen-free conditions. This study was car-
ried out in strict accordance with the Public Health Service Policy on Humane Care and Use of Labo-
ratory Animals and Association for Assessment and Accreditation of Laboratory Animal Care
accreditation guidelines. The protocol was approved by the University of Georgia Institutional Ani-
mal Care and Use Committee.
Parasites and host cells
To generate bioluminescent parasites, CL-3, ARC-0704 and Colombiana T. cruzi strains were trans-
fected with the pTREX-Luciferase-Neo plasmid, generated by cloning of the firefly luciferase gene
from the Luciferase-pcDNA3 plasmid (gift from William Kaelin; Addgene plasmid # 18964) into the
multi-cloning site of the pTREX plasmid (Vazquez and Levin, 1999). Colombiana bioluminescent
parasites were transfected with pTREX-Td-tomato plasmid (Canavaci et al., 2010) to generate para-
sites co-expressing bioluminescent and fluorescent markers. Transfection and selection conditions
were as previously described (Peng et al., 2014). For single-cell cloning, parasites were deposited
into a 96-well plate to a density of 1 cell/well using a MoFlow XDP (Beckman Coulter, Hialeah, FL)
cell sorter and cultured in 250 ml LDNT supplemented with 300 mg/ml G418. Selected clones were
screened for luciferase activity as previously described (Lewis et al., 2014) and a highly luciferase-
expressing clone was selected for in vivo experiments. To obtain metacyclic forms, epimastigotes
were submitted to stress in triatome artificial urine (TAU) medium for 2 hr. Then, parasites were incu-
bated in complemented TAU medium (TAU3AAG))(Bourguignon et al., 1998) for 6–7 days, at which
time transformation to metacyclic trypomastigote was maximal. Vero cells were obtained from the
American Type Culture Collection (Manassas, VA) and cultured in RPMI 1640 medium with 10% fetal
bovine serum. Human foreskin fibroblast (HFF) cells were a gift from Dr. Drew Etheridge (University
of Georgia) and were maintained in DMEM media supplemented with 10% fetal bovine serum. Cul-
tures were maintained in a humid atmosphere containing 5% CO2 at 37˚C and tested periodically
for mycoplasma contamination.
In vivo imaging
Luciferase- and Tdtomato-expressing parasites were used to assess in vivo parasite replication and
clearance in mice. For bioluminescent detection, mice were injected via an intraperitoneal (i.p.) route
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with D-luciferin (150 mg/kg; PerkinElmer, Waltham, MA) and anesthetized using 2.5% (vol/vol) gas-
eous isofluorane in oxygen prior to imaging on an IVIS 100 imager (Xenogen, Alameda, CA) as previ-
ously described (Canavaci et al., 2010). Quantification of bioluminescence and data analysis was
performed using Living Image v4.3 software (Xenogen).
In vitro infection and EdU detection
EdU incorporation into amastigote DNA was detected using the Click-iT EdU Imaging Kit (Thermo-
Fisher Scientific, Waltham, MA) following manufacturer specifications. Briefly, Vero cells (1  105
cells) were plated onto sterile glass-bottom 35 mm petri dishes and incubated overnight ON at
37˚C, 5% CO2, in RPMI-1640 medium plus 10% fresh fetal bovine serum (FBS). Trypomastigotes of
the colombiana, CL, Brazil or ARC-0704 strains were used to infect dishes at a ratio of 10 parasites
to one host cell. After ON infection, cell cultures were washed with RPMI and incubated with 100
mM EdU for 24, 48 or 72 hr prior to fixation, staining and mounting in ProLong Diamond anti-fade
mounting solution (ThermoFisher Scientific, Waltham, MA) containing 4’,6-diamidino-2-phenylindole
dihydrochloride (DAPI) to stain nuclear and kinetoplast DNA. Images were acquired using a laser
scanning confocal microscope LSM 710 attached to an EXFO Xcite series 120Q lamp and a digital
Zeiss XM10 camera.
Ex vivo bioluminescence imaging
C57BL/6 mice were infected with 2.5  105 colombiana T. cruzi strain trypomastigotes co-expressing
fluorescent (Tdtomato) and luminescent (luciferase) proteins. Sixty days post-infection, mice were
injected i.p. with 10 mM EdU and sacrificed 12, 48 or 72 hr later. Before bioluminescence imaging,
mice were transcardially perfused with 1x PBS and then with D-luciferin (0.3 mg/ml) diluted in 1x
PBS. Tissue-specific ex vivo luciferase imaging was performed with tissues soaked in D-luciferin (0.3
mg/ml). Luciferase positive thick tissue sections were excised and consecutive imaging and section-
ing were performed to reduce non-luminescent area and increase chances to localize amastigote
infected tissues. Selected tissue sections were washed in 1x PBS and fixed with cold 4% PFA. After
4˚C ON fixation, tissues were washed with 1x PBS and immersed in CUBIC clarifying solution
(Susaki et al., 2015) (25 % N,N,N0,N0-Tetrakis (2-hydroxypropyl) ethylenediamine; 25% urea; 15%
Triton X-100 and distilled water) with shaking at 37˚C during 2 days. After clarification, EdU incorpo-
ration on intracellular amastigotes was detected as previously described.
Tissue microscopy
For selection of parasite-containing tissue areas for further imaging in non-drug treated mice, lucifer-
ase-positive thick tissue sections were excised and consecutive imaging and sectioning were per-
formed to obtain small tissue sections with the brightest luminescent foci. Tissue sections were fixed
and clarified as described above, and EdU incorporation on intracellular amastigotes was detected
by click chemistry as described above. Tissue sections were placed into sterile glass-bottom 35 mm
petri dishes, mounted using ProLong Diamond anti-fade solution and prepared for confocal imaging
using a Zeiss LSM 710 attached to an EXFO Xcite series 120Q lamp and a digital Zeiss XM10 camera.
In the case of abdominal adipose tissue from drug-treated mice, wherein parasites were extremely
scarce, both unfixed and PFA-fixed, non-clarified tissues were scanned for parasites using a 40X
objective.
DNA fragmentation detection using TUNEL assays
DNA fragmentation indicative of parasite death was assessed by TUNEL (Terminal deoxynucleotidyl
transferase-mediated dUTP Nick End Labeling) assay according to manufacturer’s protocol (Click-iT
TUNEL Alexa Fluor 647 imaging assay; ThermoFisher Scientific, Waltham, MA). Briefly, Vero cells (1
 105) were infected with 1  106 colombiana strain trypomastigotes for approximately 12 hr. Sev-
enty-two hours post-infection, cells were washed twice in PBS, fixed with 4% PFA and then washed
again in PBS. After permeabilization with 0.2% Triton X-100, the cells were incubated with TdT reac-
tion cocktail and washed twice with 3% BSA. Finally, cells were incubated with click-iT reaction buffer
and washed with 3% BSA. Parasites were pre-treated for 10 min at room temperature with 10 IU/mL
DNase I prior to the TUNEL for positive control. A negative control was performed in the absence of
the terminal transferase. Cells were mounted using ProLong Diamond anti-fade mounting solution
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containing DAPI for parasite nuclei visualization. Results were quantified counting about 200 cells in
duplicate from three independent experiments.
Labelling of parasites with fluorescent dyes
Cell suspensions of T. cruzi trypomastigotes were labelled with CellTrace Violet fluorescent dye
(CellTrace Cell Proliferation Kit, ThermoFisher Scientific, Waltham, MA) and CFSE following manufac-
turer’s instructions. Briefly, 2  106 trypomastigotes were incubated for 20 min at 37˚C with 10 mM
of CellTrace Violet or for 5 min with 5 mM of CFSE, protected from light. Unbound dye was
quenched by the addition of five volumes of 10% FBS-RPMI or one volume of FBS respectively. After
washing in fresh media parasites were used for infection of cell cultures or mice.
Live cell imaging
Human foreskin fibroblasts (HFF) or Vero cells were seeded in 96 well glass bottom plates (Corning
Life Sciences, NY) or 8 well 1 m-slides (Ibidi, Fitchburg, WI) and infected with Tdtomato-expressing
colombiana or CL strain parasites labeled with CellTrace Violet in ratios of 2:1 to 10:1 (parasites:host
cells). For time-lapse video of amastigote replication, extracellular trypomastigotes were removed
by washing and plates were placed in humid chamber with CO2 and imaged at 40X magnification
every 15 min for 48 hr in a Lionheart FX imager (BioTek, Winooski, VT). Images and time lapse videos
were analyzed with the Gene5 software (BioTek). Live cell imaging of cultures at different times
post-infection and after drug addition or removal were performed in a Cytation5 cell imager (BioTek)
or a Delta Vision II Microscope System (GE Healthcare Biosciences, PA).
Flow cytometry and cell sorting
Vero cell cultures were infected with CellTrace Violet-labeled Tdtomato-expressing parasites of
colombiana or CL strain (5:1 ratio parasites:host cells) and incubated for 6 days at 37C in 5% CO2.
Free trypomastigotes released to the supernatant were harvested and imaged using an Image-
Stream Mark II (MilliporeSigma, MA). CellTrace Violet- Tdtomato- positive parasites from those
supernatants were sorted using a MoFlo XDP (Beckman Coulter, FL) and placed in fresh Vero cell
cultures that were periodically monitored and imaged using a Cytation five imager (BioTek).
In vitro drug treatment and washout assays
Gamma-irradiated Vero cells at 25,000/well were infected with 150,000 colombiana or CL strain
Tdtomato-luciferase trypomastigotes in each well of a 96 well plate (Greiner Bio-one) for 24 hr. After
removing non-infecting trypomastigotes, 10 mM BZN (approx. 10X IC50) in complete RPMI media
was added. The six replicate wells for each condition were read using BioTek Synergy Hybrid reader
and images were taken by BioTek Cytation 5. At the indicated times post-treatment, BZN was
removed, cultures washed and fresh medium without BZN added. Spent medium was removed and
fresh medium with or without BZN were added weekly. Additional (15,000/well) Vero cells were
added biweekly. The relative in vitro resistance to drug treatment by T. cruzi lines was determined
as previously described (Canavaci et al., 2010), and IC50 was calculated using the GraphPad PRISM
5.0 software.
Statistical analysis
The Mann-Whitney U tests and one-way variance analysis (ANOVA) of the GraphPad Prism version
5.0 software were used. Values are expressed as means ± standard error of mean of at least three
separate experiments. P values equal to or minor that 0.05 were considered significant.
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